Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1Breast Diseases 1

Interventions

Cisplatin 4pembrolizumab 3selpercatinib 2pralsetinib 2Pemetrexed 2Paclitaxel 2Fulvestrant 2Carboplatin 2trametinib 1ribociclib 1repotrectinib 1patritumab 1palbociclib 1golotimod 1exemestane 1dabrafenib 1cobimetinib 1alectinib 1abemaciclib 1Vemurafenib 1Taxes 1Tamoxifen 1STX-478 1Radiotherapy, Intensity-Modulated 1Nimorazole 1Metformin 1Letrozole 1Imlunestrant 1Gemcitabine 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × Imlunestrant × Head & Neck × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡